Dendritic Cell Based, Nusantara Vaccine Enters International Journal

JAKARTA - Finding vaccines that can last long and be effective against viruses with high mutation rates such as SARS-CoV-2 is still a challenge today.

In a publication entitled 'Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic', in this journal 'Frontier in Immunology', the role of dendritic cells (DC) and T cells in the SARS-CoV-2 infection pathogenic infection and the formation of immunity are in the spotlight.

"The approach is currently being developed in Indonesia and is known as the Nusantara Vaccine," the article wrote.

The article, which was published on September 6, wrote that a number of vaccines that were available experienced a decrease in effectiveness and required booster administration.

As a professional antigen test cell, dendritic cells can also activate the immune system, especially T cells.

"This ability makes dendritic cells have been developed as vaccines for several types of diseases. In SARS-CoV-2 infections, T cells play an important role in eliminating viruses, and their existence can be detected in the long term," the journal wrote.

Because of that, the writing continued, this condition shows that the formation of T-cell immunity is very important to prevent and control the journey of disease.

"The making of a vaccine that is oriented to induce a strong T-cell response can be formed by utilizing dendritic cells. This article discusses and describes the role of dendritic cells and T cells in the pathogenesis of SARS-CoV-2 infection and summarizes the important role of dendritic cells in the formation of T-cell immunity," the article continued.

"With the issuance of the Nusantara Vaccine in this journal, it shows that the Nusantara Vaccine is made not without scientific basis," said the Main Researcher of the Nusantara Vaccine, Colonel dr. Jonny in his statement.

Dr. Jonny added, the first published in the journal 'Expert Review of Vaccine', provides an overview of the reasons why we make Nusantara Vaccine outside the body.

"Secondly, which is now being published in Frontier in Immunology provides an illustration of why the Nusantara Vaccine uses Dendritic cells," he said.

Separately, the founder of the Beranda Ruangan Discussion, Dar Edi Yoga, said that the Indonesian nation should be proud of the publication of the results of clinical trials of the Nusantara Vaccine in the international medical journal.

"This is the only result of clinical trials of vaccines related to handling the Covid outbreak that are included in international medical journals and published twice in a row," said Dar Edi Yoga, who is also a member of the Indonesian Vox Point Expert Council.

According to him, it is time for the Indonesian government to facilitate vaccines made by the nation's children, because this is the first vaccine in the world to use dendistrict cells to prevent the corona virus.

"It is proven that this vaccine makes you healthy and strong because there have been many testimonies after the volunteers were vaccinated. If the results are not good, of course the state officials will not use it," he concluded.